Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study
Status:
Not yet recruiting
Trial end date:
2031-12-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to determine the safety, feasibility, and efficacy of
senolytics in older adults with amnestic mild cognitive impairment (MCI) or early-stage AD
(Clinical Dementia Rating (CDR)=0.5 or 1) who are tau PET positive
Phase:
Phase 2
Details
Lead Sponsor:
Wake Forest University Health Sciences
Collaborators:
Mayo Clinic The University of Texas Health Science Center at San Antonio